Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic myeloid leukemia.

Junia V Melo1, Timothy P Hughes, Jane F Apperley

  • 1Department of Haematology, Imperial College, Hammersmith Hospital, London, UK.

Hematology. American Society of Hematology. Education Program
|November 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Favorable tolerability of asciminib <i>versus</i> ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia.

Haematologica·2026
Same author

Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib.

Leukemia·2026
Same author

Allosteric and ATP-Pocket BCR::ABL1 Inhibition In Vitro, and Characterising Ex Vivo Thrombo-Inflammatory Biomarkers and Thrombin Generation in Asciminib-Treated CML Patients.

International journal of molecular sciences·2026
Same author

A Novel CIP2A and BCL-XL Clinical Diagnostic Toolkit to Predict Disease Progression and Treatment-Free Remission in Chronic Myeloid Leukaemia.

International journal of molecular sciences·2026
Same author

Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemia.

British journal of haematology·2026
Same author

Identification of a Novel, Oncogenic and Targetable <i>TPR::ABL2</i> Fusion Gene in T-Cell Acute Lymphoblastic Leukaemia.

EJHaem·2026
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Chronic myeloid leukemia (CML) treatment advances leverage the BCR-ABL oncogene discovery. Personalized strategies and molecular monitoring guide effective management for CML patients.

Area of Science:

  • Hematologic neoplasias
  • Oncology
  • Molecular biology

Background:

  • Chronic myeloid leukemia (CML) is linked to the Philadelphia chromosome and BCR-ABL oncogene.
  • CML serves as a model for understanding molecular mechanisms and targeted therapies in cancer.
  • Recent advancements have elucidated CML signal transduction pathways and their clinical translation.

Purpose of the Study:

  • To review the biological basis of CML targeted therapy.
  • To discuss current and potential treatment tools for CML.
  • To explore patient-specific treatment strategies for CML.

Main Methods:

  • Review of basic CML biology and targeted therapy design.
  • Discussion of molecular-specific drug mechanisms and novel compounds.

Related Experiment Videos

  • Explanation of molecular monitoring of response to imatinib mesylate.

    • Main Results:

    • Targeted therapies based on CML molecular biology are effective.
    • Molecular monitoring, including RT/PCR and cytogenetics, guides clinical management.
    • New compounds show promise for alternative or combination chemotherapy.

    Conclusions:

    • Understanding CML biology enables targeted therapeutic approaches.
    • Molecular monitoring is crucial for managing CML treatment response.
    • Individualized treatment strategies are essential for optimal CML patient care.